Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Wolmark N, Mamounas EP, Baehner FL, Butler SM, Tang G, Jamshidian F, Sing AP, Shak S, Paik S. Wolmark N, et al. Among authors: sing ap. J Clin Oncol. 2016 Jul 10;34(20):2350-8. doi: 10.1200/JCO.2015.62.6630. Epub 2016 May 23. J Clin Oncol. 2016. PMID: 27217450 Free PMC article.
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N. Mamounas EP, et al. Among authors: sing ap. J Natl Cancer Inst. 2017 Jan 25;109(4):djw259. doi: 10.1093/jnci/djw259. Print 2017 Jan. J Natl Cancer Inst. 2017. PMID: 28122895 Free PMC article. Clinical Trial.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Lawrence Wickerham D, Costantino JP, Wolmark N. Mamounas EP, et al. Among authors: sing ap. Breast Cancer Res Treat. 2018 Feb;168(1):69-77. doi: 10.1007/s10549-017-4550-8. Epub 2017 Nov 11. Breast Cancer Res Treat. 2018. PMID: 29128898 Free PMC article. Clinical Trial.
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
King TA, Lyman JP, Gonen M, Voci A, De Brot M, Boafo C, Sing AP, Hwang ES, Alvarado MD, Liu MC, Boughey JC, McGuire KP, Van Poznak CH, Jacobs LK, Meszoely IM, Krontiras H, Babiera GV, Norton L, Morrow M, Hudis CA. King TA, et al. Among authors: sing ap. J Clin Oncol. 2016 Jul 10;34(20):2359-65. doi: 10.1200/JCO.2015.63.1960. Epub 2016 Mar 21. J Clin Oncol. 2016. PMID: 27001590 Free PMC article.
Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.
Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J; Study investigators and study participants. Manders JB, et al. Among authors: sing ap. Ann Surg Oncol. 2017 Mar;24(3):660-668. doi: 10.1245/s10434-016-5583-7. Epub 2016 Oct 4. Ann Surg Oncol. 2017. PMID: 27704370 Free PMC article.
The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
Alvarado M, Carter DL, Guenther JM, Hagans J, Lei RY, Leonard CE, Manders J, Sing AP, Broder MS, Cherepanov D, Chang E, Eagan M, Hsiao W, Schultz MJ. Alvarado M, et al. Among authors: sing ap. J Surg Oncol. 2015 Jun;111(8):935-40. doi: 10.1002/jso.23933. Epub 2015 May 28. J Surg Oncol. 2015. PMID: 26031501
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Yardley DA, Peacock NW, Shastry M, Burris HA 3rd, Bechhold RG, Hendricks CB, Yoshizawa CN, Sing AP, Hainsworth JD. Yardley DA, et al. Among authors: sing ap. Breast Cancer Res Treat. 2015 Nov;154(2):299-308. doi: 10.1007/s10549-015-3613-y. Epub 2015 Oct 27. Breast Cancer Res Treat. 2015. PMID: 26507191 Clinical Trial.
27 results